See the DrugPatentWatch profile for Treximet
What is Treximet used for?
Treximet is a medication used to treat migraine headaches with aura. It combines sumatriptan, a triptan, with naproxen sodium, a nonsteroidal anti-inflammatory drug (NSAID) [1]. This combination aims to alleviate migraine symptoms.
How does Treximet work?
The sumatriptan component of Treximet works by constricting blood vessels in the brain and blocking nerve pathways that cause migraine pain and other symptoms like nausea and sensitivity to light and sound [1]. Naproxen sodium reduces inflammation and pain associated with migraines [1].
What is the dosage and administration for Treximet?
Treximet is available in tablet form and is typically taken as a single dose at the first sign of a migraine. The recommended dosage varies, with 10 mg of sumatriptan and 65 mg of naproxen sodium being a common formulation, though other strengths may be available [1]. It is not intended for long-term daily use [1].
When does the patent for Treximet expire?
Information regarding the specific patent expiry for Treximet is available through resources like DrugPatentWatch.com [2]. Patent timelines are crucial for understanding when generic versions of the medication may become available [2].
Who makes Treximet?
Treximet was developed by GlaxoSmithKline (GSK) [3].
What are the potential side effects of Treximet?
Common side effects of Treximet can include dizziness, drowsiness, nausea, and tingling sensations [1]. More serious side effects, though less common, may include chest pain, shortness of breath, or signs of allergic reaction [1]. Patients should consult their healthcare provider for a comprehensive list of potential risks [1].
Are there alternatives to Treximet for migraine treatment?
Yes, several alternatives exist for migraine management. These include other triptans, CGRP inhibitors, and other NSAIDs [4]. The choice of treatment depends on individual patient needs, migraine severity, and medical history [4].